Homepage / Technology / Finally, the first new drug for sickle cell anemia in 20 years
Как Стать Стримером Казино%3F Что для Этого Нужно%3 Best Game Software How to Design Engaging and Effective Educational Events Winline Делает Разницу! Букмекерская Контора Winline Онлайн Ставки На Спорт Making Corporate Travel Arrangements Business Virtual Data Room Stock Market Tips For Beginners What to Look for in a VDR Provider Why You Need a Secure Data Room Learning in the Digital Age How to Apply For Business Loans VDR and Document Management Performance Management and HR Outsourcing Modern Business Integration How to Choose the Right Board Portal Software for Your Company How to Choose a Data Storage Room Why Startups Use a Data Room for Investors The Best Web Tools for Designers Use Cases For Using VDR Documents Subsidy Programs and Financing Innovative Technologies for Audit What Is Real Estate Management? Investment and Funds Inspiring Teaching Books What Are the Benefits of a Virtual Data Room? Startups and Business Ideas How to Improve Virtual Board Communication The Lego Company History Investing in the Biotech Industry Financial Startup Basics Jogue Por Dinheiro Actual Em Cassino Onlin Virtual Communication Methods for Remote Leaders How to Choose the Best VDR Providers How Successful Online Businesses Succeed How Business Experts Fuel Innovation and Create Competitive Edge The IT World and Business Deal Making Software and How it Can Help Your Business Virtual Data Room Software Types of Steel Materials and Their Uses Board of Directors Software Bonver Casino Cz Hrací Automaty S Bonusem Zdarm Magazyn Żużel Speedway W Polsce I Na Świeci What Is Logistics School? What Is the VDR for Acquisition? The Best Data Room Apps For Startups Best Practices for Creating an Effective Board Meeting Agenda How to Choose the Best Shareholders Online Platforms Ostdeutsche Biersorten Getting a Construction Management Degree How to Select an Online Data Room Provider Start Your Blog Without Investment What to Look for in a Board Room Provider Data Room Comparison – Which Data Room Is Right For Your Business? Zakłady Sportowe Online Autógrafo Bukmacherska 1xbe “Pin-up O Melhor Cassino Do Brasil Web Site Oficial ᐈ Jogar Caça-níquei Rotating Events in Our Time How to Choose the Best Business Software Choosing an Online Payment Processor Due Diligence Software Virtual Data Room Providers for M&A Due Diligence The Best Online Data Room Benefits of a Due Diligence Data Room Best Practices for Data Rooms Types of Corporate Governance What Is Virtual Data Storage? Benefits of Document Distribution Software The Benefits of a Data Room for Startups Effective Project Management Requires a Mix of Technical and People Skills Top 5 Free File Sharing Services Zakłady Sportowe Online Obstawiaj U Bukmachera Gg Be Speed Up Your Business Valuation With a Data Room How to Choose the Best Board Management Software for Business How to Write Effective Board Decision Papers Choosing Board Meeting Software The Benefits of Document Distribution Software Why Startups Need a VDR for Start-Up Virtual Data Room for Ipos and the IPO Process What is a Board Portal? What Industries Use Virtual Data Room? Advantages of a Data Room What Does a Board Room Provider Do? Data Room Analysis for Venture Capital Funding The Importance of Board Reporting Software Safe Uploading and Downloading Business Files How to Select the Best Board Management Software How to Organize the Work of a Company “gerçek Parayla En Iyi Slot Makineleri Ve Spor Bahisler Which is the Best Podcast For Stock Market Beginners? Virtual Data Room Facts How to Protect Confidential Documents for Boards Advantages of Online Meetings Business Issues to Consider When Choosing a Data Room Provider What Is a Data Room? Virtual Board Room Software Due Diligence Risk Factors How to Choose a Reliable Tool for Data Exchange test Users535352253 Board Software and VDR Programs Business Operations Management Software

Technology

Finally, the first new drug for sickle cell anemia in 20 years

In early July the Food and Drug Administration approved the first new drug for sickle cell patients in nearly 20 years. It was a watershed moment for people who suffer from the rare blood disorder that can cause debilitating pain. And for one physician it was the end of a 25-year journey.

The drug, Endari, is made by Emmaus and has been approved for patients five years and older. It injects glutamine into red blood cells, reducing the likelihood they will clog and cause painful blockages in small blood vessels and, in some cases, organs.

Sickle cell disease primarily affects African Americans, Latinos and other minority groups. It’s a lifelong disorder in which red blood cells, normally round, are crescent- (or sickle-) shaped, due to abnormal hemoglobin. That shape makes the cells less flexible, or more ‘sticky,’ which can impede blood flow. By injecting glutamine into the cells, Endari makes the cells less ‘sticky.’ It’s not a permanent solution, but it does help reduce the pain.

“We knew this was not going to cure the disease, but improve the conditions [for patients],” says Yutaka Niihara, MD, CEO of Emmaus. “We’re able to decrease the symptoms and make the circulation better.”

Sickle cell affects about 100,000 people in the United States, a number that’s dwarfed by people suffering from cancer, heart disease and other high-profile ailments. That number could actually be higher, but many patients are viewed as “drug seekers” by some members of the medical community, due to the severe pain they face. As a result, they may not be diagnosed with sickle cell.

More from Modern Medicine:
New hope for a vaccine to fight Gonorrhea
New tools to combat the organ transplant crisis
A.I.’s expanding role in medicine

Still, that official patient count made sickle cell an “orphan disease” in the eyes of most pharmaceutical companies, which ignored it for decades because of the perceived fear that development costs on any drugs would not be recouped.

Niihara first saw the disease in 1989, he says, when training in hemotology. He had planned to specialize in cancer, but after seeing sickle cell’s impact on patients, he changed his focus to researching the disease.

He first approached the FDA with the research for what would become Endari in 2000 and was given a $1 million grant to begin a Phase 2 clinical study.

From there, he says, he planned to pass it on to an established pharmaceutical company to continue the research, but he couldn’t find an interested company. As a result, he started Emmaus.

Now that Endari has received approval, he says, he intends to ensure it is an affordable drug so patients can relieve their suffering.

“Typically, the way pharmaceutical companies make money on a new medication is to charge enormous amounts of money for treatment,” he says. “Treatment for an orphan [disease] can cost $200,000 to $300,000 per year. Some can be more. That’s not our goal at all. We’re going to try to keep our price of a fully dosed patient below $20K. We’re sill finalizing pricing with our agency, but that’s what I’m asking.”

Emmaus, he says, has roughly an 85 percent margin on the product, so if it treats just 10
percent of the patients in the United States, it would result in more than $100 million in revenue.

“For a small biotech, that’s big money,” he says.

Should European approvals come, the market jumps to $2 billion, he says.

The approval of Endari has won praise from sickle cell advocacy groups, though they’re encouraging federal regulators and drug makers to speed up the pace of treatment research for the disease.

“More effort and resources still need to be dedicated to nutritional supplementation studies aimed at establishing specific RDAs (recommended dietary allowances) for sickle cell patients, much like the specific RDAs developed for cystic fibrosis, pregnancy and growth within the general population,” said Lanetta Bronté, president of the Foundation for Sickle Cell Disease Research.

Before the FDA’s approval of Endari, sickle cell patients most commonly were treated with Hydroxyurea, a drug that’s also used in chemotherapy. Endari, like any drug, has potential side effects. The FDA reported those could include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain. But Niihara says, it doesn’t have toxicity.

“As a physician who is always facing sickle cell patients, I appreciated [Hydroxyurea], but at the same time, I wanted to provide something that doesn’t have toxicity — something where patients didn’t have to worry about birth defects or … worry they might develop cancer in the future.”

Endari may have broken a long drought in sickle cell treatments, but it could have lots of company soon. As of last year, there were a dozen other drugs still in development for the disease.

— By Chris Morris, special to CNBC.com

Source: Tech CNBC
Finally, the first new drug for sickle cell anemia in 20 years

Comments are closed.